Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $73.67

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has received a consensus rating of "Reduce" from the five brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $73.67.

A number of brokerages have commented on MCRB. Chardan Capital reiterated a "neutral" rating and issued a $6.00 price objective (up previously from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a report on Friday, March 14th. Finally, Wall Street Zen upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th.

Seres Therapeutics Price Performance

NASDAQ MCRB traded up $0.13 on Wednesday, reaching $7.22. The company had a trading volume of 88,626 shares, compared to its average volume of 146,242. Seres Therapeutics has a 1 year low of $6.53 and a 1 year high of $30.60. The firm has a 50-day moving average of $9.71 and a 200-day moving average of $13.93. The firm has a market capitalization of $63.05 million, a PE ratio of -31.39 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($1.57). As a group, sell-side analysts expect that Seres Therapeutics will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A number of hedge funds have recently bought and sold shares of MCRB. Goldman Sachs Group Inc. raised its stake in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after buying an additional 21,679 shares in the last quarter. Avantax Advisory Services Inc. increased its holdings in shares of Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 28,500 shares during the last quarter. Jane Street Group LLC raised its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 37,866 shares in the last quarter. Northern Trust Corp raised its position in shares of Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its stake in Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 48,013 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.